
First-in-class SIK2 inhibitor enters Phase I trial
Nimbus Therapeutics has dosed the first subjects in its Phase I clinical trial of NDI-225673, a highly selective inhibitor of salt-inducible kinase 2 (SIK2) for the potential treatment of immune-mediated inflammatory diseases. The Phase I trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and… Read More













